ClinicalTrials.gg
RecruitingNCT06074276Updated Jun 18, 2024

The Effects of Almond on Facial Skin Collagen and Wrinkles

An interventional study of Food: whole almonds and Food: non-nut snack in Collagen Degeneration, Wrinkle and Pigmentation, sponsored by Integrative Skin Science and Research. Recruiting at 1 site in United States. Open to female participants aged 35 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Integrative Skin Science and Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
35 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Ehlers-Danlos Syndrome with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ehlers-Danlos Syndrome · United States.

Planned enrollment
7th of 15
60 · median 60
Started
2023
with 3 others
No phase
13 of 26
7 open now
Primary completion
2024-09
later than 0 of 10 live
Registered
19th of 26
by date
Lead sponsor
2 of 26
Integrative Skin Science and Research

Among the 26 studies in Ehlers-Danlos Syndrome with a site in United States, this one is the 7th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2023, is one of 13 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 19th registered.

Ehlers-Danlos Syndrome

67 studies on the registry are indexed under Ehlers-Danlos Syndrome; 24 are open to participants now.

Browse Ehlers-Danlos Syndrome studies →

Open to participants now

9 of the 26 studies in Ehlers-Danlos Syndrome with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Ehlers-Danlos Syndrome studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 35 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Ehlers-Danlos Syndrome with a site in United States, or all of them as a file.
02

Study summary

Investigate the effects of almond consumption on collagen production, elastin levels, wrinkles, and pigmentation among premenopausal women and postmenopausal women belonging to all Fitzpatrick skin types.

Read the detailed description

Almonds are energy-dense and rich in beneficial nutrients including B vitamins, vitamin E, mono- and polyunsaturated fatty acids, protein, fiber, minerals and polyphenols. Polyphenols and vitamin E in almonds provide protection to the body in part, through their ability to combat oxidative stress. Clinical studies have demonstrated beneficial effects of almond consumption on diseases such as diabetes and cardiovascular disease.

Almond consumption has been shown to significantly decrease wrinkle severity in two clinical studies conducted with postmenopausal women with Fitzpatrick skin type I and II. Almond intake has also been shown to increase resistance to erythema induced by ultraviolet exposure. The extracellular matrix contains proteins including collagen and elastin, which contributes to the integrity of the skin. Enzymatic and ultraviolet radiation induced degradation and a reduction in synthesis of collagen and elastin contribute to wrinkle formation. Furthermore, the process of menopause decreases the level of estrogen which affects the skin in several ways, including a decrease in skin collagen and hydration, and an increase in wrinkling.

03

Conditions studied

  • Collagen Degeneration
  • Wrinkle
  • Pigmentation
  • Elastic Skin

Browse trials for

04

Who can participate

Ages eligible
35 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects 35 to 70 years of age of all skin types
  • 50% of the subjects will be women determined as >1-year loss of menstrual period
  • 50% of the subjects will be premenopausal women
  • 18.5 - 35 kg/m2
  • Individuals with a habitual diet that has been maintained for at least 6 months and to be maintained for the duration of the study
  • Individuals must maintain their usual skincare products, defined as products that has been used for at least 1 month, for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Those with a nut allergy
  • Those who are unwilling to discontinue oral collagen supplementation 1 month prior to the start of the study
  • Individuals who are unwilling to discontinue vitamin E or nut containing supplements 2 weeks prior to and during the intervention.
  • Individuals who are pregnant or breastfeeding
  • Change in skincare products during the study
  • Had a medical or cosmetic procedure such as laser resurfacing or plastic surgery to the face within the last 6 months (include botulinum toxin, dermal fillers, collagen, or other similar cosmetic procedure)
  • Has an photosensitive condition or known genetic condition with a deficiency in collagen production (such as Ehler-Danlos)
  • Those with a skin disease on their face that would affect the assessment of their skin based on the assessment of the investigator.
  • Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Almonds

    Consumption of almonds 5 times per week

    Other: Food: whole almonds

  • Placebo comparator
    Control Snack

    Consumption of protein and calorie matched non-nut-based food 5 times per week

    Other: Food: non-nut snack

Interventions

  • OtherFood: whole almonds

    60 grams or (\~2 oz) will be consumed 5 times per week.

  • OtherFood: non-nut snack

    Protein and calorie matched non-nut-based food will be consumed 5 times per week by mouth

06

What researchers measure

Primary outcomes

  1. Skin collagen and elastin quantification

    Assess with biopsy based histological examination

    Time frame: 24 weeks

  2. Facial wrinkles

    Wrinkle severity score measured by Facial Image Analysis System (BTBP 3D image analysis system). Higher scores indicate worsened wrinkle severity and lower scores represent improvement in wrinkle severity.

    Time frame: 24 weeks

Secondary outcomes

  1. Pigment intensity score

    Change in the appearance of facial pigmentation by high resolution photography (BTBP Clarity Pro) and measures intensity of facial pigmentation. Higher scores indicate darker pigmentation.

    Time frame: 12 Weeks

  2. Pigment intensity score

    Change in the appearance of facial pigmentation by high resolution photography (BTBP Clarity Pro) and measures intensity of facial pigmentation. Higher scores indicate darker pigmentation.

    Time frame: 24 Weeks

  3. Expression of enzymes that either degrade collagen (MMP1) or inhibit collagen degradation (TIMP1) on skin biopsies

    Assess through biopsy based histological examination

    Time frame: 24 Weeks

  4. Plasma for potential AGE (advanced glycation end products) analysis

    Blood samples will be collected

    Time frame: 12 Weeks

  5. Plasma for potential AGE (advanced glycation end products) analysis

    Blood samples will be collected

    Time frame: 24 Weeks

  6. Facial Wrinkles

    Wrinkle severity score measured by Facial Image Analysis System (BTBP 3D image analysis system). Higher scores indicate worsened wrinkle severity and lower scores represent improvement in wrinkle severity.

    Time frame: 12 Weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Sep 2024, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2023
First posted
Oct 10, 2023
StartActual
Oct 4, 2023
Primary completionEst.
Sep 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06074276
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Oct 4, 2023
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jun 18, 2024

Study contacts

Sarah Adnan
Contact
sarah@integrativeskinresearch.com
9168074299
Raja Sivamani, MD MS AP
principal investigator · Integrative Skin Science and Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion